Ac Immune SA (ACIU) — 6-K Filings

6-K Filings (28)

• 6-K Filing — Apr 7, 2026
• 6-K Filing — Dec 11, 2025
• AC Immune SA Files 6-K Report — Nov 4, 2025 Risk: low
  AC Immune SA filed a Form 6-K on November 4, 2025, reporting for the month of November 2025. The filing is a report of a foreign private issuer and is incorpora
• AC Immune SA Cuts Workforce by 30% to Focus on Key Assets — Sep 4, 2025 Risk: medium
  On September 4, 2025, AC Immune SA announced a strategic review resulting in a sharpened focus on its key assets, including three clinical-stage immunotherapy p
• AC Immune SA Files 6-K Report — Aug 5, 2025 Risk: low
  AC Immune SA filed a Form 6-K on August 5, 2025, reporting for the period ending June 30, 2025. The filing is a report of a foreign private issuer and is incorp
• AC Immune SA Holds Annual Shareholder Meeting, Votes on Agenda Items — Jun 20, 2025 Risk: low
  On June 19, 2025, AC Immune SA held its Annual General Meeting of Shareholders. The company announced the final voting results on the agenda items, with the Man
• AC Immune Appoints Interim EVP of Development — Jun 11, 2025 Risk: low
  AC Immune SA announced the appointment of Dr. Günther Staffler as interim Executive Vice President, Development, effective immediately. Dr. Staffler, who joined
• AC Immune SA Announces 2025 AGM Details and Board Changes — May 19, 2025 Risk: low
  AC Immune SA announced its 2025 Annual General Meeting (AGM) invitation and proxy card on May 19, 2025, for the meeting scheduled on June 19, 2025. The company
• AC Immune SA Files April 2025 6-K Report — Apr 30, 2025 Risk: low
  AC Immune SA filed a Form 6-K on April 30, 2025, reporting for the month of April 2025. This filing is incorporated by reference into their existing registratio
• AC Immune SA Files March 2025 6-K with Press Release and 2024 Report — Mar 13, 2025 Risk: low
  AC Immune SA filed a Form 6-K on March 13, 2025, reporting its activities for March 2025. The filing includes a press release dated March 13, 2025, and its 2024
• AC Immune SA Announces Key Executive Promotions — Dec 18, 2024 Risk: low
  AC Immune SA announced on December 18, 2024, the internal promotions of three key employees, effective January 1, 2025. Mark Danton will become Executive Vice P
• AC Immune SA Reports Interim Data for Down Syndrome Trial — Dec 10, 2024 Risk: medium
  On December 10, 2024, AC Immune SA announced interim safety and tolerability data from its ABATE Phase 1b/2 trial for ACI-24.060, an immunotherapy targeting amy
• AC Immune SA Reports Positive Phase 2 Parkinson's Trial Data — Nov 14, 2024 Risk: medium
  On November 14, 2024, AC Immune SA announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial for ACI-7104.056, an anti-al
• AC Immune SA Files Form 6-K for November 2024 — Nov 5, 2024 Risk: low
  AC Immune SA filed a Form 6-K on November 5, 2024, reporting for the month of November 2024. This filing is a report of a foreign private issuer and will be inc
• AC Immune Appoints New Chief Medical Officer — Sep 19, 2024 Risk: low
  On September 19, 2024, AC Immune SA announced the appointment of Dr. Anke Post, MD PhD, as its new Chief Medical Officer (CMO) and a member of the Executive Com
• AC Immune to Receive CHF 24.6M Milestone from Janssen — Sep 17, 2024 Risk: medium
  On September 17, 2024, AC Immune SA announced it will receive a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, Inc. This payment is
• AC Immune Partner LMI Gets FDA Fast Track for Tau PET Diagnostic — Aug 28, 2024 Risk: medium
  On August 28, 2024, AC Immune SA announced that its partner, Life Molecular Imaging (LMI), received U.S. FDA Fast Track Designation for the Tau PET diagnostic,
• AC Immune SA Files 6-K Report — Aug 6, 2024 Risk: low
  AC Immune SA filed a Form 6-K on August 6, 2024, reporting for the period ending June 30, 2024. The filing is a report of a foreign private issuer and is incorp
• AC Immune SA Replaces ATM Program with Jefferies LLC — Aug 6, 2024 Risk: low
  On August 6, 2024, AC Immune SA entered into a new Open Market Sales Agreement with Jefferies LLC, replacing its previous at-the-market program. This agreement
• AC Immune Unveils Novel Neurodegenerative Drug Candidates — Jul 31, 2024 Risk: medium
  On July 31, 2024, AC Immune SA announced the unveiling of morADC, a new class of drug candidates for neurodegenerative diseases. This announcement was made via
• AC Immune's Alzheimer's Drug JNJ-2056 Gets FDA Fast Track — Jul 25, 2024 Risk: medium
  On July 25, 2024, AC Immune SA announced that its active-immunotherapy candidate, JNJ-2056 (formerly ACI-35.030), targeting phosphorylated Tau (pTau) for Alzhei
• AC Immune SA Holds Annual Meeting, Updates Shareholders — Jun 20, 2024 Risk: low
  On June 20, 2024, AC Immune SA held its Annual General Meeting of Shareholders. The company provided an operational update and announced the final voting result
• AC Immune SA Files 6-K for Shareholder Meetings — May 21, 2024 Risk: low
  AC Immune SA filed a Form 6-K on May 21, 2024, announcing an invitation to its Ordinary Shareholders' Meeting and its 2024 Annual General Meeting. The filing de
• AC Immune SA Files Form 6-K with SEC — May 13, 2024 Risk: low
  AC Immune SA filed a Form 6-K on May 13, 2024, reporting information as a foreign private issuer. The filing is incorporated by reference into several of their
• AC Immune Grants Takeda Option for ACI-24.060 — May 13, 2024 Risk: medium
  On May 13, 2024, AC Immune SA entered into an Option and License Agreement with Takeda Pharmaceuticals, USA, Inc. This agreement grants Takeda an option to obta
• AC Immune SA Files 6-K, Includes 2023 Annual Report — Mar 14, 2024 Risk: low
  AC Immune SA filed a Form 6-K on March 14, 2024, to report its 2023 Annual Report and a press release dated March 14, 2024. The filing includes information abou
• AC Immune Regains Full Rights to Alzheimer's Drugs Crenezumab, Semorinemab — Jan 22, 2024
  AC Immune SA announced on January 22, 2024, the termination of two research collaboration and license agreements with Genentech, Inc. and F-Hoffman La-Roche Ltd
• AC Immune Updates Phase 2 Alzheimer's & Parkinson's Trials — Jan 3, 2024
  AC Immune SA, a Swiss biopharmaceutical company, filed a 6-K on January 3, 2024, providing a progress update on its Phase 2 active immunotherapy clinical pipeli

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX